我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Diagnosis Cell Lung Cancer with Bone Metastases: An Over View

Ping Wang

Rarely have the characteristics and prognostic factors of SCLC patients with bone metastases at first diagnosis been discussed. The purpose of this study was to examine these patients' prognostic factors and create a survival scoring system to support clinical treatment decisions. Retrospective review was conducted on the records of 102 SCLC patients with bone metastasis at the time of diagnosis who were seen at our hospital between May 2010 and May 2015. Potential clinical survival predictors were evaluated using the log-rank test and multivariate Cox regression analysis. Based on the hazard ratios of significant independent prognostic factors, a scoring system was developed. The spine was the most common location for bone metastases (64.7%), and 26 patients (25.6%) had just one bone metastasis. The 2-year survival rate was 10.3%, and the median survival time was 10.4 months. Independently, age, the number of bone metastases, and the occurrence of extraosseous distant metastases had a significant impact on overall survival. Patients were placed into one of three groups based on their scores. The three groups had median survival times of 6.4 months, 8.5 months, and 12.4 months, respectively, and 2-year survival rates of 0%, 2.9%, and 19.3% (p=0.000). Radiation to the bone (22.5%) and spinal cord compression (11.8%) were the most common skeletal-related events (SREs) in 26 patients (25.5%). At the time of diagnosis, this study includes preliminary clinical data from SCLC patients with bone metastases